The Business of RNAi Therapeutics in 2012.
作者信息
Haussecker Dirk
机构信息
Department of Medical Biotechnology, College of Natural Sciences, Dongguk University, Seoul, Korea.
出版信息
Mol Ther Nucleic Acids. 2012 Feb 7;1(2):e8. doi: 10.1038/mtna.2011.9.
Abstract
摘要
相似文献
1
The Business of RNAi Therapeutics in 2012.2012年的RNA干扰疗法业务。
Mol Ther Nucleic Acids. 2012 Feb 7;1(2):e8. doi: 10.1038/mtna.2011.9.
2
Current issues of RNAi therapeutics delivery and development.RNAi 治疗药物递送与研发的当前问题。
J Control Release. 2014 Dec 10;195:49-54. doi: 10.1016/j.jconrel.2014.07.056. Epub 2014 Aug 9.
3
Physiologically based pharmacokinetic (PBPK) modeling of RNAi therapeutics: Opportunities and challenges.基于生理学的 RNA 干扰治疗药物药代动力学建模：机遇与挑战。
Biochem Pharmacol. 2021 Jul;189:114468. doi: 10.1016/j.bcp.2021.114468. Epub 2021 Feb 10.
4
The business of RNAi therapeutics.RNA干扰疗法的业务。
Hum Gene Ther. 2008 May;19(5):451-62. doi: 10.1089/hum.2008.007.
5
Delivery of RNAi Therapeutics to the Airways-From Bench to Bedside.RNA干扰疗法在气道中的应用——从 bench 到 bedside。
注：bench 到 bedside 直译为“从实验台到病床边”，常表示从实验室研究成果转化到临床应用的过程，这里意译为“从基础研究到临床应用”可能更符合语境，但按照要求保留直译。
Molecules. 2016 Sep 20;21(9):1249. doi: 10.3390/molecules21091249.
6
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges.基于纳米颗粒的 RNAi 治疗药物递送：进展与挑战。
Pharmaceuticals (Basel). 2013;6(1):85-107. doi: 10.3390/ph6010085.
7
Imaging-guided delivery of RNAi for anticancer treatment.用于抗癌治疗的RNA干扰的成像引导递送
Adv Drug Deliv Rev. 2016 Sep 1;104:44-60. doi: 10.1016/j.addr.2016.01.008. Epub 2016 Jan 22.
8
RNAi therapeutics: an antiviral strategy for human infections.RNAi 疗法：一种针对人类感染的抗病毒策略。
Curr Opin Pharmacol. 2020 Oct;54:121-129. doi: 10.1016/j.coph.2020.09.011. Epub 2020 Nov 7.
9
RNAi therapeutics for CNS disorders.中枢神经系统疾病的 RNAi 治疗。
Brain Res. 2010 Jun 18;1338:112-21. doi: 10.1016/j.brainres.2010.03.038. Epub 2010 Mar 20.
10
A Review of pH-Responsive Organic-Inorganic Hybrid Nanoparticles for RNAi-Based Therapeutics.pH 响应型有机-无机杂化纳米粒子用于基于 RNAi 的治疗的综述。
Macromol Biosci. 2021 Sep;21(9):e2100183. doi: 10.1002/mabi.202100183. Epub 2021 Jun 23.
引用本文的文献
1
The future of siRNA-mediated approaches to treat von Willebrand disease.用于治疗血管性血友病的小干扰RNA介导方法的未来。
Expert Rev Hematol. 2025 Feb;18(2):109-122. doi: 10.1080/17474086.2025.2459259. Epub 2025 Jan 29.
2
Recent advances in understanding of the mechanisms of RNA interference in insects.昆虫RNA干扰机制研究的最新进展
Insect Mol Biol. 2024 Jul 3. doi: 10.1111/imb.12941.
3
Human papillomavirus in the setting of immunodeficiency: Pathogenesis and the emergence of next-generation therapies to reduce the high associated cancer risk.免疫功能低下人群中的人乳头瘤病毒：发病机制和新一代疗法的出现，以降低相关癌症的高风险。
Front Immunol. 2023 Mar 7;14:1112513. doi: 10.3389/fimmu.2023.1112513. eCollection 2023.
4
The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease.开发用于治疗帕金森病的 miRNA 疗法的前景与挑战。
Cells. 2020 Mar 31;9(4):841. doi: 10.3390/cells9040841.
5
Editorial focus: understanding off-target effects as the key to successful RNAi therapy.社论重点：理解脱靶效应是 RNAi 治疗成功的关键。
Cell Mol Biol Lett. 2019 Dec 9;24:69. doi: 10.1186/s11658-019-0196-3. eCollection 2019.
6
Small RNAs in parasitic nematodes - forms and functions.寄生线虫中的小 RNA——种类与功能。
Parasitology. 2020 Jul;147(8):855-864. doi: 10.1017/S0031182019001689. Epub 2019 Dec 17.
7
Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery.重新点燃 RNAi 疗法：体内 siRNA 递送的材料设计要求。
Adv Mater. 2019 Dec;31(49):e1903637. doi: 10.1002/adma.201903637. Epub 2019 Sep 30.
8
Ki67 targeted strategies for cancer therapy.Ki67 靶向治疗策略在癌症治疗中的应用。
Clin Transl Oncol. 2018 May;20(5):570-575. doi: 10.1007/s12094-017-1774-3. Epub 2017 Oct 20.
9
Therapeutic miRNA and siRNA: Moving from Bench to Clinic as Next Generation Medicine.治疗性微小RNA和小干扰RNA：作为新一代药物从实验室走向临床
Mol Ther Nucleic Acids. 2017 Sep 15;8:132-143. doi: 10.1016/j.omtn.2017.06.005. Epub 2017 Jun 12.
10
Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin In Vivo.脂质纳米颗粒介导的小干扰RNA向骨细胞的递送导致体内SOST的有效沉默和骨硬化蛋白的抑制。
Mol Ther Nucleic Acids. 2016 Sep 13;5(9):e363. doi: 10.1038/mtna.2016.68.
本文引用的文献
1
Structural diversity repertoire of gene silencing small interfering RNAs.基因沉默小干扰 RNA 的结构多样性库。
Nucleic Acid Ther. 2011 Jun;21(3):125-31. doi: 10.1089/nat.2011.0286.
2
Branched RNA nanostructures for RNA interference.分支 RNA 纳米结构用于 RNA 干扰。
Chem Commun (Camb). 2011 Aug 7;47(29):8367-9. doi: 10.1039/c1cc11780g. Epub 2011 Jun 21.
3
RNA interference and its potential applications to chronic HBV treatment: results of a Phase I safety and tolerability study.RNA干扰及其在慢性乙肝治疗中的潜在应用：一项I期安全性和耐受性研究的结果
Antivir Ther. 2011;16(4):547-54. doi: 10.3851/IMP1798.
4
Thermodynamic stability of small hairpin RNAs highly influences the loading process of different mammalian Argonautes.小发夹 RNA 的热力学稳定性极大地影响了不同哺乳动物 Argonautes 的加载过程。
Proc Natl Acad Sci U S A. 2011 May 31;108(22):9208-13. doi: 10.1073/pnas.1018023108. Epub 2011 May 16.
5
Characterization of side reactions during the annealing of small interfering RNAs.小干扰 RNA 退火过程中副反应的特征。
Anal Biochem. 2011 Jul 1;414(1):47-57. doi: 10.1016/j.ab.2011.02.040. Epub 2011 Mar 2.
6
RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer.针对 survivin 和 PLK1 的 RNAi 治疗药物治疗膀胱癌。
Mol Ther. 2011 May;19(5):928-35. doi: 10.1038/mt.2011.21. Epub 2011 Mar 1.
7
Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa.抑制和替代基因疗法治疗显性视网膜炎色素变性的常染色体显性疾病的小鼠模型。
Mol Ther. 2011 Apr;19(4):642-9. doi: 10.1038/mt.2010.293. Epub 2011 Jan 11.
8
Polymer-related off-target effects in non-viral siRNA delivery.聚合物相关的非病毒 siRNA 递送中的脱靶效应。
Biomaterials. 2011 Mar;32(9):2388-98. doi: 10.1016/j.biomaterials.2010.11.081. Epub 2010 Dec 22.
9
High-density lipoprotein facilitates in vivo delivery of α-tocopherol-conjugated short-interfering RNA to the brain.高密度脂蛋白促进 α-生育酚偶联的短干扰 RNA 在体内递送至脑内。
Hum Gene Ther. 2011 Jun;22(6):711-9. doi: 10.1089/hum.2010.083. Epub 2011 Mar 21.
10
On firm ground: IP protection of therapeutic nanoparticles.站稳脚跟：治疗性纳米颗粒的知识产权保护
Nat Biotechnol. 2010 Dec;28(12):1267-70. doi: 10.1038/nbt.1725.
Zotero 插件